Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test

Vox Sanguinis

Volumn 102, Issue 2, 2012, Pages 159-166

  Hochsmann B ^a,b   Leichtle, R ^a,b   von Zabern, I ^a,b   Kaiser, S ^a,b   Flegel, W A ^a,b,c   Schrezenmeier, H ^a,b  

^a German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Direct antiglobulin test positive by C3d; Eculizumab; Paroxysmal nocturnal haemoglobinuria

Indexed keywords

BILIRUBIN; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C3D; ECULIZUMAB; FERRITIN; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; COOMBS TEST; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAINTENANCE THERAPY; MALE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; FEMALE; FERRITINS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84856020291     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2011.01530.x     Document Type: Article

References (17)

1. Dacie JV: Paroxysmal nocturnal haemoglobinuria. Proc R Soc Med 1963; 56:587-596.
2. Oni SB, Osunkoya BO, Luzzatto L: Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells. Blood 1970; 36:145-152.
3. Miyata T, Takeda J, Iida Y, et al.: The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993; 259:1318-1320.
4. Mortazavi Y, Merk B, McIntosh J, et al.: The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot. Blood 2003; 101:2833-2841.
5. Hillmen P, Lewis SM, Bessler M, et al.: Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333:1253-1258.
6. Parker C, Omine M, Richards S, et al.: Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106:3699-3709.
7. Rother RP, Rollins SA, Mojcik CF, et al.: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25:1256-1264.
8. Brodsky RA, Young NS, Antonioli E, et al.: Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111:1840-1847.
9. Hillmen P, Hall C, Marsh JC, et al.: Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350:552-559.
10. Hillmen P, Young NS, Schubert J, et al.: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355:1233-1243.
11. Hillmen P, Muus P, Duhrsen U, et al.: Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110:4123-4128.
12. Berzuini A, Montanelli F, Prati D: Hemolytic anemia after eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2010; 363:993-994.
13. Hill A, Rother RP, Arnold L, et al.: Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica 2010; 95:567-573.
14. Risitano AM, Notaro R, Marando L, et al.: Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009; 113 (17):4094-4100.
15. Schrezenmeier H, Höchsmann B: Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria. Expert Rev Hematol 2009; 2:7-16.
16. Luzzatto L, Risitano AM, Notaro R: Paroxysmal nocturnal hemoglobinuria and eculizumab. Haematologica 2010; 95:523-526.
17. Armand P, Kim HT, Cutler CS, et al.: Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109:4586-4588.